18 February 2023>: Clinical Research
Comparison of 3 Enzyme-Linked Immunoassay Methods to Evaluate Serum Concentrations of Infliximab and Antibodies to Infliximab in 32 Patients with Moderate to Severe Inflammatory Bowel Disease
Tomislav Jukic 1CDEF , David Drobne 2ABCDE , Sasa Pusavec 3BF , Alojz Ihan 3AE , David Stubljar 4ACDE* , Andrej Starc 5DEDOI: 10.12659/MSM.939084
Med Sci Monit 2023; 29:e939084
Table 2 Measured IFX levels according to the 3 methods.
Patient ID | TL IFX (μg/mL) – UHL | TL IFX (μg/mL) – apDia | TL IFX (μg/mL) – Lisa-Tracker |
---|---|---|---|
1 | 5.17 | 8.57 | 8.89 |
2 | 1.12 | 1.37 | 1.45 |
3 | 0.90 | 1.34 | 1.33 |
4 | 1.84 | 2.98 | 3.51 |
5 | 5.16 | 6.76 | 6.27 |
6 | 6.93 | 10.7 | 7.62 |
7 | 5.94 | 9.80 | 7.83 |
8 | 6.51 | 8.38 | 7.87 |
9 | >12 | >12 | 15.3 |
10 | 7.26 | 10.3 | 11.1 |
11 | 1.02 | 1.46 | 1.50 |
12 | 10.6 | >12 | 8.77 |
13 | 4.68 | 6.31 | 5.07 |
14 | 6.56 | 6.16 | 5.21 |
15 | 8.54 | 8.27 | 7.50 |
16 | 7.46 | ND | 8.11 |
17 | 4.86 | ND | 6.16 |
18 | ND | ND | ND |
ND – not detectable. |